2.18
-0.07(-3.11%)
Currency In USD
| Previous Close | 2.25 |
| Open | 2.25 |
| Day High | 2.3 |
| Day Low | 2.17 |
| 52-Week High | 7.92 |
| 52-Week Low | 1 |
| Volume | 305,629 |
| Average Volume | 1.06M |
| Market Cap | 67.69M |
| PE | -1.11 |
| EPS | -1.97 |
| Moving Average 50 Days | 2.01 |
| Moving Average 200 Days | 1.8 |
| Change | -0.07 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $123.93 as of December 26, 2024 at a share price of $2.18. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 2 years ago, it would be worth $522.78 as of December 26, 2024 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Launches Pancreatic Cancer Advisory Board
GlobeNewswire Inc.
Dec 19, 2024 1:00 PM GMT
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - C
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
GlobeNewswire Inc.
Dec 17, 2024 1:00 PM GMT
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIR
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
GlobeNewswire Inc.
Dec 12, 2024 1:00 PM GMT
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibito